Arkolith/Insider Trading/ACRS/Form 4

Balthaser Kevin

Chief Financial OfficerAclaris Therapeutics, Inc. (ACRS) · full profile →Form 4 · filed Jan 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2026Tax withholding(F)4K$2.88$13K160K
Jan 2, 2026Option exercise(M)13K——165K
Jan 1, 2026Option exercise(M)8K——154K
Jan 1, 2026Tax withholding(F)2K$3.01$7K152K
Dec 31, 2025Tax withholding(F)20K$3.01$60K146K
Dec 31, 2025Option exercise(M)74K——166K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2026Option exercise(M)13K—$014K
Jan 1, 2026Option exercise(M)8K—$08K
Dec 31, 2025Option exercise(M)74K—$00

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001957554-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML